{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T13:37:53Z","timestamp":1783777073556,"version":"3.55.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Onasemnogene abeparvovec has been life-changing for children with spinal muscular atrophy (SMA), signifying the potential and progress occurring in gene- and cell-based therapies for rare genetic diseases. Hence, it is important that clinicians gain knowledge and understanding in gene therapy-based treatment strategies for SMA. In this review, we describe the development and translation of onasemnogene abeparvovec from clinical trials to healthcare practice and share knowledge on the facilitators and barriers to implementation. Rapid and accurate SMA diagnosis, awareness, and education to safely deliver gene therapy to eligible patients and access to expertise in multidisciplinary management for neuromuscular disorders are crucial for health system readiness. Early engagement and intersectoral collaboration are required to surmount complex logistical processes and develop policy, governance, and accountability. The collection and utilisation of real-world evidence are also an important part of clinical stewardship, informing ongoing improvements to care delivery and access. Additionally, a research-enabled clinical ecosystem can expand scientific knowledge and discovery to optimise future therapies and magnify health impacts. Important ethical, equity, economic, and sustainability issues are evident, for which we must connect globally.<\/jats:p>","DOI":"10.1186\/s40348-023-00171-5","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T03:01:28Z","timestamp":1700017288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gene therapy-based strategies for spinal muscular atrophy\u2014an Asia-Pacific perspective"],"prefix":"10.1186","volume":"10","author":[{"given":"Michelle A.","family":"Farrar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loudella","family":"Calotes-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranil","family":"De Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lani","family":"Attwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Cini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ferrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didu S.","family":"Kariyawasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,15]]},"reference":[{"issue":"1","key":"171_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S et al (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80(1):155\u2013165","journal-title":"Cell"},{"issue":"2","key":"171_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1086\/338627","volume":"70","author":"M Feldkotter","year":"2002","unstructured":"Feldkotter M et al (2002) Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 70(2):358\u2013368","journal-title":"Am J Hum Genet"},{"issue":"1","key":"171_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jpeds.2012.05.067","volume":"162","author":"MA Farrar","year":"2013","unstructured":"Farrar MA et al (2013) Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatr 162(1):155\u2013159","journal-title":"J Pediatr"},{"issue":"7","key":"171_CR4","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/14737175.2023.2218549","volume":"23","author":"L Balaji","year":"2023","unstructured":"Balaji L et al (2023) Decision-making and challenges within the evolving treatment algorithm in spinal muscular atrophy: a clinical perspective. Expert Rev Neurother 23(7):571\u2013586","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"171_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S2352-4642(22)00342-X","volume":"7","author":"DS Kariyawasam","year":"2023","unstructured":"Kariyawasam DS et al (2023) Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study. Lancet Child adolesc health 7(3):159\u2013170","journal-title":"Lancet Child adolesc health"},{"issue":"3","key":"171_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41436-019-0673-0","volume":"22","author":"DST Kariyawasam","year":"2020","unstructured":"Kariyawasam DST et al (2020) The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet Med 22(3):557\u2013565","journal-title":"Genet Med"},{"issue":"6","key":"171_CR7","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","volume":"31","author":"T Dangouloff","year":"2021","unstructured":"Dangouloff T et al (2021) Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go. Neuromuscular disorders : NMD 31(6):574\u2013582","journal-title":"Neuromuscular disorders : NMD"},{"key":"171_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ibneur.2023.01.009","volume":"14","author":"N Wijekoon","year":"2023","unstructured":"Wijekoon N et al (2023) Gene therapy for selected neuromuscular and trinucleotide repeat disorders - an insight to subsume South Asia for multicenter clinical trials. IBRO neurosci rep 14:146\u2013153","journal-title":"IBRO neurosci rep"},{"issue":"1","key":"171_CR9","first-page":"152","volume":"261","author":"CL Bladen","year":"2014","unstructured":"Bladen CL et al (2014) Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America. Austral Europe J Neurol 261(1):152\u2013163","journal-title":"Austral Europe J Neurol"},{"issue":"3","key":"171_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/ana.26299","volume":"91","author":"CJJ Yeo","year":"2022","unstructured":"Yeo CJJ et al (2022) Ethical perspectives on treatment options with spinal muscular atrophy patients. Ann Neurol 91(3):305\u2013316","journal-title":"Ann Neurol"},{"issue":"8","key":"171_CR11","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1136\/jnnp-2019-322327","volume":"91","author":"D Kariyawasam","year":"2020","unstructured":"Kariyawasam D et al (2020) Great expectations: virus-mediated gene therapy in neurological disorders. J Neurol Neurosurg Psychiatry 91(8):849\u2013860","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"171_CR12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell JR et al (2021) Current clinical applications of in vivo gene therapy with AAVs. Mol Ther 29(2):464\u2013488","journal-title":"Mol Ther"},{"issue":"24","key":"171_CR13","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMc2212912","volume":"388","author":"CG B\u00f6nnemann","year":"2023","unstructured":"B\u00f6nnemann CG et al (2023) Dystrophin immunity after gene therapy for Duchenne\u2019s muscular dystrophy. N Engl J Med 388(24):2294\u20132296","journal-title":"N Engl J Med"},{"issue":"4","key":"171_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/mus.27363","volume":"64","author":"EA Kichula","year":"2021","unstructured":"Kichula EA et al (2021) Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. Muscle Nerve 64(4):413\u2013427","journal-title":"Muscle Nerve"},{"issue":"3","key":"171_CR15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","volume":"74","author":"D Chand","year":"2021","unstructured":"Chand D et al (2021) Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol 74(3):560\u2013566","journal-title":"J Hepatol"},{"issue":"10","key":"171_CR16","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","volume":"44","author":"JW Day","year":"2021","unstructured":"Day JW et al (2021) Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy. Drug Saf 44(10):1109\u20131119","journal-title":"Drug Saf"},{"key":"171_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","volume":"231","author":"DH Chand","year":"2021","unstructured":"Chand DH et al (2021) Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J Pediatr 231:265\u2013268","journal-title":"J Pediatr"},{"issue":"15-16","key":"171_CR18","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1089\/hum.2020.217","volume":"31","author":"PB Shieh","year":"2020","unstructured":"Shieh PB et al (2020) Re: \u201cMoving forward after two deaths in a gene therapy trial of myotubular myopathy\u201d by Wilson and Flotte. Hum Gene Ther 31(15-16):787","journal-title":"Hum Gene Ther"},{"issue":"18","key":"171_CR19","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377(18):1713\u20131722","journal-title":"N Engl J Med"},{"issue":"4","key":"171_CR20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW et al (2021) Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 20(4):284\u2013293","journal-title":"Lancet Neurol"},{"issue":"10","key":"171_CR21","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E et al (2021) Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 20(10):832\u2013841","journal-title":"Lancet Neurol"},{"issue":"7","key":"171_CR22","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA et al (2022) Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial. Nat Med 28(7):1381\u20131389","journal-title":"Nat Med"},{"issue":"7","key":"171_CR23","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA et al (2022) Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase III SPR1NT trial. Nat Med 28(7):1390\u20131397","journal-title":"Nat Med"},{"issue":"1","key":"171_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12967-019-02154-5","volume":"17","author":"L Riva","year":"2019","unstructured":"Riva L et al (2019) A few ethical issues in translational research for gene and cell therapy. J Transl Med 17(1):395","journal-title":"J Transl Med"},{"issue":"9","key":"171_CR25","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/jnnp-2017-317412","volume":"89","author":"MA Farrar","year":"2018","unstructured":"Farrar MA et al (2018) Nusinersen for SMA: expanded access programme. J Neurol Neurosurg Psychiatry 89(9):937\u2013942","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"171_CR26","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/jnnp-2021-326344","volume":"92","author":"ST Shih","year":"2021","unstructured":"Shih ST et al (2021) Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis. J Neurol Neurosurg Psychiatry 92(12):1296\u20131304","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"171_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/dmcn.15117","volume":"64","author":"AM D'Silva","year":"2022","unstructured":"D'Silva AM et al (2022) Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme. Dev Med Child Neurol 64(5):625\u2013632","journal-title":"Dev Med Child Neurol"},{"key":"171_CR28","first-page":"100742","volume":"33","author":"DST Kariyawasam","year":"2021","unstructured":"Kariyawasam DST et al (2021) \u201cWe needed this\u201d: perspectives of parents and healthcare professionals involved in a pilot newborn screening program for spinal muscular atrophy. E Clin Med 33:100742","journal-title":"E Clin Med"},{"issue":"6","key":"171_CR29","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1111\/hex.13625","volume":"25","author":"CQ Nguyen","year":"2022","unstructured":"Nguyen CQ et al (2022) \u2018Advocacy groups are the connectors\u2019: experiences and contributions of rare disease patient organization leaders in advanced neurotherapeutics. Health expect 25(6):3175\u20133191","journal-title":"Health expect"},{"issue":"3","key":"171_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.31128\/AJGP-06-21-6028","volume":"51","author":"AJ Newson","year":"2022","unstructured":"Newson AJ et al (2022) Ethical aspects of the changing landscape for spinal muscular atrophy management in Australia. Austral j general pract 51(3):131\u2013135","journal-title":"Austral j general pract"},{"issue":"2","key":"171_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JND-190468","volume":"7","author":"J Glascock","year":"2020","unstructured":"Glascock J et al (2020) Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2. J neuromusc disease 7(2):97\u2013100","journal-title":"J neuromusc disease"},{"issue":"6","key":"171_CR32","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ana.26358","volume":"91","author":"S Deng","year":"2022","unstructured":"Deng S et al (2022) The 4-copy conundrum in the treatment of infants with spinal muscular atrophy. Ann Neurol 91(6):891","journal-title":"Ann Neurol"},{"issue":"2","key":"171_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/JND-200475","volume":"7","author":"W M\u00fcller-Felber","year":"2020","unstructured":"M\u00fcller-Felber W et al (2020) Infants diagnosed with spinal muscular atrophy and 4 SMN2 copies through newborn screening - opportunity or burden? J neuromusc disease 7(2):109\u2013117","journal-title":"J neuromusc disease"},{"key":"171_CR34","doi-asserted-by":"crossref","unstructured":"Ricci M et al (2023) Clinical phenotype of pediatric and adult patients with spinal muscular atrophy with four SMN2 copies: are they really all stable? Ann Neurol","DOI":"10.1002\/ana.26788"},{"issue":"4","key":"171_CR35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/PEP.0b013e3182351f04","volume":"23","author":"AM Glanzman","year":"2011","unstructured":"Glanzman AM et al (2011) Validation of the Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Pediatr Phys Ther 23(4):322\u2013326","journal-title":"Pediatr Phys Ther"},{"issue":"9","key":"171_CR36","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS et al (2014) Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurol 83(9):810\u2013817","journal-title":"Neurol"},{"issue":"3","key":"171_CR37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/acn3.51519","volume":"9","author":"AM D'Silva","year":"2022","unstructured":"D'Silva AM et al (2022) Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy. Ann clin translat neurol 9(3):339\u2013350","journal-title":"Ann clin translat neurol"},{"key":"171_CR38","first-page":"101997","volume":"59","author":"M Pane","year":"2023","unstructured":"Pane M et al (2023) Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in na\u00efve patients with spinal muscular atrophy and following switch from other therapies. E Clin Med 59:101997","journal-title":"E Clin Med"},{"issue":"6","key":"171_CR39","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/dmcn.15135","volume":"64","author":"KA Carey","year":"2022","unstructured":"Carey KA et al (2022) Family, healthcare professional, and societal preferences for the treatment of infantile spinal muscular atrophy: a discrete choice experiment. Dev Med Child Neurol 64(6):753\u2013761","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"171_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/jnnp-2020-324254","volume":"92","author":"D Kariyawasam","year":"2020","unstructured":"Kariyawasam D et al (2020) Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen. J Neurol Neurosurg Psychiatry 92(1):78\u201385","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"171_CR41","doi-asserted-by":"crossref","unstructured":"D'Silva AM et al (2023) Identification of novel CSF-derived miRNAs in treated paediatric onset spinal muscular atrophy: an exploratory study. Pharmaceutics 15(1)","DOI":"10.3390\/pharmaceutics15010170"},{"issue":"7","key":"171_CR42","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/j.ymthe.2023.03.032","volume":"31","author":"GJ Logan","year":"2023","unstructured":"Logan GJ et al (2023) Structural and functional characterization of capsid binding by anti-AAV9 monoclonal antibodies from infants after SMA gene therapy. Molecul ther 31(7):1979\u20131993","journal-title":"Molecul ther"},{"issue":"9","key":"171_CR43","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1080\/14712598.2022.2066471","volume":"22","author":"HJ McMillan","year":"2022","unstructured":"McMillan HJ et al (2022) Onasemnogene abeparvovec for the treatment of spinal muscular atrophy. Expert Opin Biol Ther 22(9):1075\u20131090","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"171_CR44","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/dmcn.15442","volume":"65","author":"A Livingstone","year":"2023","unstructured":"Livingstone A et al (2023) The ethics of crowdfunding in paediatric neurology. Dev Med Child Neurol 65(4):450\u2013455","journal-title":"Dev Med Child Neurol"},{"issue":"3-4","key":"171_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/0972753120950069","volume":"27","author":"N Samaranayake","year":"2020","unstructured":"Samaranayake N et al (2020) What we fail to see in neuro-genetic diseases: a bird\u2019s eye view from the developing world. Ann Neurosci 27(3-4):91\u201397","journal-title":"Ann Neurosci"},{"issue":"12","key":"171_CR46","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/S1474-4422(20)30405-1","volume":"19","author":"N Wijekoon","year":"2020","unstructured":"Wijekoon N et al (2020) A biobank in Sri Lanka that links East and West. Lancet Neurol 19(12):972","journal-title":"Lancet Neurol"},{"key":"171_CR47","doi-asserted-by":"crossref","unstructured":"D'Silva AM et al (2023) Identification of novel CSF-derived miRNAs in treated paediatric onset spinal muscular atrophy: an exploratory study. Pharmaceutics 15(1)","DOI":"10.3390\/pharmaceutics15010170"},{"issue":"1","key":"171_CR48","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/bmjinnov-2020-000425","volume":"7","author":"M Carvalho","year":"2021","unstructured":"Carvalho M et al (2021) Patient access to gene therapy medicinal products: a comprehensive review. BMJ Inn 7(1):123\u2013134","journal-title":"BMJ Inn"},{"issue":"11","key":"171_CR49","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41582-020-00410-7","volume":"16","author":"MA Farrar","year":"2020","unstructured":"Farrar MA et al (2020) Spinal muscular atrophy - the dawning of a new era. Nat Rev Neurol 16(11):593\u2013594","journal-title":"Nat Rev Neurol"},{"issue":"3-4","key":"171_CR50","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41434-021-00284-4","volume":"30","author":"JE Adair","year":"2023","unstructured":"Adair JE et al (2023) Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI). Gene Ther 30(3-4):216\u2013221","journal-title":"Gene Ther"},{"issue":"1","key":"171_CR51","doi-asserted-by":"publisher","first-page":"1355203","DOI":"10.1080\/20016689.2017.1355203","volume":"5","author":"J J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen J et al (2017) Annuity payments can increase patient access to innovative cell and gene therapies under England\u2019s net budget impact test. J market access health policy 5(1):1355203","journal-title":"J market access health policy"},{"key":"171_CR52","unstructured":"Powell T, O\u2019Donnell M (2019) NICE appraisals of rare disease. https:\/\/researchbriefings.files.parliament.uk\/documents\/CDP-2019-0022\/CDP-2019-0022.pdf"},{"key":"171_CR53","unstructured":"Web Annex A (2023) World Health Organization Model List of Essential Medicines \u2013 23rd List, 2023. In: The selection and use of essential medicines 2023: Executive summary of the report of the 24th WHO Expert Committee on the Selection and Use of Essential Medicines, 24 \u2013 28 April 2023. World Health Organization, Geneva. (WHO\/MHP\/HPS\/EML\/2023.02). Licence: CC BY NC-SA 3.0 IGO"},{"issue":"1","key":"171_CR54","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s13023-021-01923-0","volume":"16","author":"WA Gahl","year":"2021","unstructured":"Gahl WA et al (2021) Essential list of medicinal products for rare diseases: recommendations from the IRDiRC Rare Disease Treatment Access Working Group. Orphanet J Rare Dis 16(1):308","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"171_CR55","doi-asserted-by":"publisher","first-page":"e807","DOI":"10.1016\/S2352-3026(22)00327-1","volume":"9","author":"JE Adair","year":"2022","unstructured":"Adair JE et al (2022) Place-of-care manufacturing of gene therapies. Lancet Haematol 9(11):e807\u2013e808","journal-title":"Lancet Haematol"},{"key":"171_CR56","unstructured":"WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-fifth report. World Health Organization, Geneva. 2021. (WHO Technical Report Series, No. 1033). Licence: CC BY-NC-SA 3.0 IGO p. 269-304"},{"issue":"6","key":"171_CR57","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3233\/JND-221538","volume":"9","author":"EF Tizzano","year":"2022","unstructured":"Tizzano EF et al (2022) Clinical trial readiness for spinal muscular atrophy: experience of an international educational-training initiative. J neuromusc disease 9(6):809\u2013820","journal-title":"J neuromusc disease"},{"key":"171_CR58","doi-asserted-by":"crossref","unstructured":"Farrar MA et al (2020) \u201cThe whole game is changing and you've got hope\u201d: Australian perspectives on treatment decision making in spinal muscular atrophy. Patient 13(4):389-400","DOI":"10.1007\/s40271-020-00415-w"},{"issue":"1","key":"171_CR59","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13023-022-02317-6","volume":"17","author":"CQ Nguyen","year":"2022","unstructured":"Nguyen CQ et al (2022) The involvement of rare disease patient organisations in therapeutic innovation across rare paediatric neurological conditions: a narrative review. Orphanet J Rare Dis 17(1):167","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"171_CR60","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS et al (2018) Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromusc disorders: NMD 28(3):197\u2013207","journal-title":"Neuromusc disorders: NMD"},{"issue":"2","key":"171_CR61","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E et al (2018) Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromusc disorders: NMD 28(2):103\u2013115","journal-title":"Neuromusc disorders: NMD"},{"issue":"1","key":"171_CR62","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13023-022-02280-2","volume":"17","author":"AC Mahungu","year":"2022","unstructured":"Mahungu AC et al (2022) A review of the genetic spectrum of hereditary spastic paraplegias, inherited neuropathies and spinal muscular atrophies in Africans. Orphanet j rare diseas 17(1):133","journal-title":"Orphanet j rare diseas"},{"issue":"4","key":"171_CR63","doi-asserted-by":"publisher","first-page":"e200077","DOI":"10.1212\/NXG.0000000000200077","volume":"9","author":"NR Monnakgotla","year":"2023","unstructured":"Monnakgotla NR et al (2023) Analysis of structural variants previously associated with ALS in Europeans Highlights Genomic Architectural Differences in Africans. Neurol Genet 9(4):e200077","journal-title":"Neurol Genet"},{"key":"171_CR64","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fgene.2020.00054","volume":"11","author":"E Vorster","year":"2020","unstructured":"Vorster E et al (2020) Spinal muscular atrophy in the Black South African population: a matter of rearrangement? Front Genet 11:54","journal-title":"Front Genet"},{"issue":"13","key":"171_CR65","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","volume":"389","author":"A Lek","year":"2023","unstructured":"Lek A et al (2023) Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy. New England J Med 389(13):1203\u20131210","journal-title":"New England J Med"}],"container-title":["Molecular and Cellular Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-023-00171-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40348-023-00171-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-023-00171-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T04:37:38Z","timestamp":1700023058000},"score":1,"resource":{"primary":{"URL":"https:\/\/molcellped.springeropen.com\/articles\/10.1186\/s40348-023-00171-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["171"],"URL":"https:\/\/doi.org\/10.1186\/s40348-023-00171-5","relation":{},"ISSN":["2194-7791"],"issn-type":[{"value":"2194-7791","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,15]]},"assertion":[{"value":"9 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MAF and DSK have received honoraria for scientific advisory boards from Novartis Gene Therapies, Inc., Biogen, and Roche.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}